Innate Pharma SA announces today the entry into regulatory pre-clinical development of IPH 2301, a novel monoclonal antibody targeting NK (Natural Killer) and T cells. It is the first antibody from the NK platform to be developed for the treatment of inflammatory conditions.
| PR in english | 40.52 KB |
| CP en français | 42.43 KB |